Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...